Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.47 |
| ▸ | FABP7 | O15540 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21899390 | 1.00 | ACE (0.54) | ACEFABP5FABP7KMT2ADPP8 | |
| SCHEMBL30951904 | 1.00 | ACE (0.54) | ACEFABP5FABP7KMT2ADPP8 | |
| SCHEMBL8294724 | 0.89 | KMT2A (0.44) | ACEFABP5FABP7KMT2ADPP8 | |
| SCHEMBL13259983 | 0.89 | ACE (0.43) | ACEFABP5FABP7KMT2ADPP8 | |
| SCHEMBL3040971 | 0.88 | ACE (0.56) | ACEFABP5FABP7 | |
| SCHEMBL16465859 | 0.88 | ACE (0.56) | ACEFABP5FABP7 | |
| SCHEMBL800088 | 0.88 | ACE (0.56) | ACEFABP5FABP7 | |
| SCHEMBL6945507 | 0.85 | HSP90AA1 (0.49) | ACEFABP5FABP7KMT2ADPP8 | |
| SCHEMBL18961434 | 0.84 | RORC (0.44) | ACEFABP5FABP7 | |
| SCHEMBL18939840 | 0.83 | RORC (0.42) | ACEFABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335901-B1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | MERCK SERONO SA (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
| EP-1335901-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2003-08-20 | — | — | EP | disclosed |
| US-6596732-B2 | Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors. hormone known for its antidiuretic effect and its effect in regulating arterial pressure. | SANOFI-SYNTHELABO (FR) | 2003-07-22 | — | — | US | disclosed |
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2003-06-12 | — | — | US | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109545-A1 | Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same | AVPR2, AVPR1B, AVPR1A | ACE 1114/4885FABP5 1628/4885FABP7 605/4885 |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | ACE 1265/4885FABP5 3931/4885FABP7 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.